Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Northwestern University
With
National Alliance for Research on Schizophrenia and Depression
Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with olanzapine or risperidone for at least three months randomized to receive adjunctive treatment with a 5-HT1A agonist (buspirone, 15-30 mg/day)or placebo.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects must meet all of the following criteria to be eligible for participation in the current research study.
1. Subjects will be males and females between 18-65 years of age;
2. Subjects will have a definite diagnosis by DSM-IV criteria for Schizophrenia or Schizoaffective Disorder;
3. The subjects or their legal guardian must sign the informed consent;
4. Subjects currently being treated with olanzapine or risperidone for a duration of at least 3 months
You may not be if
1. Subjects who are pregnant or lactating
2. Subjects who have brain damage and/or neurological disorders
